Oculis(OCSAW)
ZUG, SwitzerlandBiotechnology
Focus: Oculis is a Switzerland-based biotech company specializing in innovative ocular drug delivery technologies, particularly dexamethasone formulations for ophthalmology indications. With 5,000+ employees, the company operates as a public entity focused on addressing unmet needs in diabetic macular edema, dry eye disease, uveitis, and optic neuritis.
Profile data last refreshed 1h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Employees
5000+
Open Jobs
0
About Oculis
AI assessmentNot HiringNo open roles listed right now. Follow Oculis to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Oculis's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
3/9 — Basic
Company HealthStrong
Pipeline
Late-stage
4 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
PHASE_2
Clinical Trials (1)
NCT05608837Multicenter Study on the Efficacy and Safety of OCS-01 in Subjects With Uveitis Related and Post Surgical Macular Edema
Phase 2Help build intelligence for Oculis
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.